ReviewElectrolyte & blood pressure : E & BP2026
Advances in Hyperkalemia Management and the Emerging Role of Sodium Zirconium Cyclosilicate.
Review in Electrolyte & blood pressure : E & BP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intrarenal Hemodynamic Mechanisms of Kidney Protection by Nonsteroidal Mineralocorticoid Receptor Antagonists.Endocrinology and metabolism (Seoul, Korea) · 2026Review
- Patient and Clinician Perspectives on Hyperkalemia Management Under Cardio-Kidney-Protective Therapy: A Three-Stakeholder Cross-Sectional Survey.Electrolyte & blood pressure : E & BP · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperkalemia is a common and potentially life-threatening complication in patients with chronic kidney disease and heart failure. It also represents a major barrier to the optimal use of renin-angiotensin-aldosterone system inhibitors (RAASi), which are central to improving cardiorenal outcomes. Contemporary guidance, including the 2025 Korean Society of Nephrology Practical Recommendations for the Management of Hypertensive Kidney Disease, emphasizes the maintenance of normokalemia as a key strategy for enabling continuation and optimization of RAASi therapy. Sodium zirconium cyclosilicate (SZC) supports this therapeutic paradigm by enabling rapid potassium reduction and sustained potassium control. This review repositions hyperkalemia as a modifiable barrier to guideline-directed therapy and summarizes the pharmacology, clinical evidence, and practical considerations related to SZC use in patients at high cardiorenal risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.